Aditxt Inc. (ADTX)vsAlnylam Pharmaceuticals Inc (ALNY)
ADTX
Aditxt Inc.
$0.00
-6.82%
HEALTHCARE · Cap: $9.48M
ALNY
Alnylam Pharmaceuticals Inc
$298.76
-4.49%
HEALTHCARE · Cap: $41.79B
Smart Verdict
WallStSmart Research — data-driven comparison
Alnylam Pharmaceuticals Inc generates 29894761% more annual revenue ($4.29B vs $14,340). ALNY leads profitability with a 12.6% profit margin vs 0.0%. ALNY earns a higher WallStSmart Score of 65/100 (B-).
ADTX
Avoid33
out of 100
Grade: F
ALNY
Strong Buy65
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ADTX.
Margin of Safety
+86.3%
Fair Value
$2354.68
Current Price
$298.76
$2055.92 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 1094.0% year-over-year
Conservative balance sheet, low leverage
Every $100 of equity generates 54 in profit
Revenue surging 96.4% year-over-year
Growing faster than its price suggests
Strong operational efficiency at 23.0%
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
0.0% earnings growth
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 37.1x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : ADTX
The strongest argument for ADTX centers on Revenue Growth, Debt/Equity. Revenue growth of 1094.0% demonstrates continued momentum.
Bull Case : ALNY
The strongest argument for ALNY centers on Return on Equity, Revenue Growth, PEG Ratio. Revenue growth of 96.4% demonstrates continued momentum. PEG of 0.54 suggests the stock is reasonably priced for its growth.
Bear Case : ADTX
The primary concerns for ADTX are EPS Growth, Market Cap, Profit Margin.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, Debt/Equity, P/E Ratio. A P/E of 78.8x leaves little room for execution misses.
Key Dynamics to Monitor
ADTX profiles as a hypergrowth stock while ALNY is a growth play — different risk/reward profiles.
ALNY carries more volatility with a beta of 0.27 — expect wider price swings.
ADTX is growing revenue faster at 1094.0% — sustainability is the question.
ALNY generates stronger free cash flow (49M), providing more financial flexibility.
Bottom Line
ALNY scores higher overall (65/100 vs 33/100) and 96.4% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Aditxt Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Aditxt Inc. is an innovative biotechnology company dedicated to transforming healthcare through its proprietary immune modulation and personalized medicine platform. Focused on enhancing immune responses to address chronic diseases and allergies, Aditxt aims to significantly improve patient outcomes. With a robust pipeline of therapeutic candidates supported by comprehensive research and strategic collaborations, the company is poised to be a leader in the rapidly evolving field of immune-based therapies. Aditxt's commitment to scientific advancement and patient-centric solutions positions it at the forefront of immunology and the broader healthcare landscape.
Visit Website →Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?